Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by American Trust

American Trust cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 18.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 27,059 shares of the biopharmaceutical company’s stock after selling 6,167 shares during the period. American Trust’s holdings in Gilead Sciences were worth $2,269,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 161 shares during the period. CarsonAllaria Wealth Management Ltd. raised its holdings in shares of Gilead Sciences by 198.3% during the second quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 238 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences during the second quarter worth approximately $33,000. Finally, Cedar Wealth Management LLC grew its holdings in Gilead Sciences by 51.6% in the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 160 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

Gilead Sciences stock opened at $92.38 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock has a market cap of $115.13 billion, a P/E ratio of 1,026.44, a P/E/G ratio of 2.38 and a beta of 0.18. The company’s fifty day simple moving average is $89.82 and its 200-day simple moving average is $79.26.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping the consensus estimate of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.29 EPS. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 4.35 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.33%. Gilead Sciences’s dividend payout ratio (DPR) is 3,422.22%.

Analyst Ratings Changes

Several analysts have weighed in on the company. Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Wolfe Research began coverage on shares of Gilead Sciences in a research report on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price for the company. Truist Financial upped their price target on shares of Gilead Sciences from $83.00 to $97.00 and gave the stock a “hold” rating in a research note on Friday, November 8th. The Goldman Sachs Group boosted their target price on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Finally, BMO Capital Markets lifted their price target on Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Insider Activity

In related news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 164,211 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares in the company, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 447,234 shares of company stock worth $41,288,086. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.